Monmouth R.E. Inv. Corp. (MNR) EPS Estimated At $0.21; Esperion Therapeutics (ESPR) Sentiment Is 1.22

November 15, 2017 - By Vivian Park

Esperion Therapeutics, Inc. is a lipid management company. The company has market cap of $1.19 billion. The Firm is a late-stage pharmaceutical firm focused on developing and commercializing once-daily,

oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol . It currently has negative earnings. With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Analysts expect Monmouth R.E. Inv. Corp. (NYSE:MNR) to report $0.21 EPS on November, 29 after the close.They anticipate $0.03 EPS change or 16.67% from last quarter’s $0.18 EPS. MNR’s profit would be $15.58 million giving it 20.70 P/E if the $0.21 EPS is correct. After having $0.19 EPS previously, Monmouth R.E. Inv. Corp.’s analysts see 10.53% EPS growth. The stock increased 0.40% or $0.07 during the last trading session, reaching $17.39. About shares traded. Monmouth R.E. Inv. Corp. (NYSE:MNR) has risen 27.78% since November 15, 2016 and is uptrending. It has outperformed by 11.08% the S&P500.

The stock decreased 1.99% or $0.94 during the last trading session, reaching $46.28. About shares traded. Esperion Therapeutics Inc (ESPR) has risen 133.75% since November 15, 2016 and is uptrending. It has outperformed by 117.05% the S&P500.

Ratings analysis reveals 0 of Esperion Therapeutics’s analysts are positive. Out of 2 Wall Street analysts rating Esperion Therapeutics, 0 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. ESPR was included in 2 notes of analysts from November 14, 2016. Citigroup downgraded Esperion Therapeutics Inc (NASDAQ:ESPR) on Monday, November 14 to “Neutral” rating. The rating was maintained by RBC Capital Markets on Thursday, February 23 with “Sector Perform”.

Analysts await Esperion Therapeutics Inc (NASDAQ:ESPR) to report earnings on February, 28. They expect $-1.80 earnings per share, down 39.53% or $0.51 from last year’s $-1.29 per share. After $-1.86 actual earnings per share reported by Esperion Therapeutics Inc for the previous quarter, Wall Street now forecasts -3.23% EPS growth.

Aisling Capital Llc holds 6.64% of its portfolio in Esperion Therapeutics Inc for 837,125 shares. Meditor Group Ltd owns 566,000 shares or 3.94% of their US portfolio. Moreover, Ra Capital Management Llc has 3.88% invested in the company for 731,531 shares. The New York-based Iguana Healthcare Management Llc has invested 2.62% in the stock. Rhenman & Partners Asset Management Ab, a Sweden-based fund reported 363,347 shares.

Investors sentiment increased to 1.52 in 2017 Q2. Its up 0.46, from 1.06 in 2017Q1. It is positive, as 14 investors sold Monmouth R.E. Inv. Corp. shares while 47 reduced holdings. 22 funds opened positions while 71 raised stakes. 43.29 million shares or 1.90% more from 42.49 million shares in 2017Q1 were reported. Bessemer owns 64,900 shares. Metropolitan Life Insurance Communications New York stated it has 50,623 shares. Morgan Stanley invested in 0% or 195,042 shares. Fmr Ltd Liability Corp invested in 0% or 346,555 shares. D E Shaw And Company has invested 0% in Monmouth R.E. Inv. Corp. (NYSE:MNR). Cutter Company Brokerage Incorporated accumulated 0.16% or 26,813 shares. Wfg Advsr L P stated it has 35,272 shares or 0.12% of all its holdings. Thrivent For Lutherans has 12,550 shares for 0% of their portfolio. Teachers Ins Annuity Association Of America accumulated 0.04% or 71,720 shares. Price T Rowe Assocs Md owns 70,328 shares or 0% of their US portfolio. Loeb Prns Corp holds 116,692 shares or 0.5% of its portfolio. Pekin Singer Strauss Asset Management Il accumulated 0.03% or 11,650 shares. First Trust Advisors Limited Partnership invested in 21,474 shares or 0% of the stock. Intrust Fincl Bank Na, Kansas-based fund reported 11,999 shares. Raymond James & Assoc owns 502,324 shares or 0.02% of their US portfolio.

Monmouth Real Estate Investment Corporation is a real estate investment trust . The company has market cap of $1.29 billion. The Company’s primary business is the ownership of real estate. It has a 58.71 P/E ratio. The Company’s investment focus is to own single tenant, industrial buildings and leased to investment-grade tenants or their subsidiaries on long-term net leases.

Since June 15, 2017, it had 1 insider purchase, and 0 selling transactions for $996 activity. Another trade for 69 shares valued at $996 was bought by Miller Kevin S..

Among 5 analysts covering Monmouth Real Estate Investment Corporation (NYSE:MNR), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Monmouth Real Estate Investment Corporation had 11 analyst reports since August 10, 2015 according to SRatingsIntel. The stock of Monmouth R.E. Inv. Corp. (NYSE:MNR) has “Buy” rating given on Thursday, May 18 by DA Davidson. The firm has “Neutral” rating given on Thursday, December 1 by DA Davidson. As per Friday, August 5, the company rating was maintained by Wunderlich. The stock of Monmouth R.E. Inv. Corp. (NYSE:MNR) has “Buy” rating given on Friday, May 5 by National Securities. Wunderlich maintained Monmouth R.E. Inv. Corp. (NYSE:MNR) rating on Friday, May 6. Wunderlich has “Buy” rating and $13 target. The stock of Monmouth R.E. Inv. Corp. (NYSE:MNR) earned “Outperform” rating by BMO Capital Markets on Monday, August 24. Wunderlich maintained Monmouth R.E. Inv. Corp. (NYSE:MNR) rating on Monday, August 10. Wunderlich has “Buy” rating and $11.50 target. The firm has “Market Perform” rating by BMO Capital Markets given on Friday, December 2. The firm earned “Buy” rating on Tuesday, July 19 by Janney Capital.

By

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>